Together, the above results indicate that noncanonical ubiquitination of JMJD1A at K918 can promote DDR gene expression, DSB repair, and resistance of prostate cancer cells to IR, topoisomerase inhibitors or PARP inhibitors. Here, KDM3A is linked to prostate cancer.